Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.

Close

We'll Tell You When It's Time to Tap Tesla

A week ago today, in a strategy story aimed at helping you survive and thrive in today’s whipsaw markets, Chief Investment Strategist Keith Fitz-Gerald told us to put Tesla Motors Inc. (Nasdaq: TSLA) on our “watch lists” for a likely future purchase.

“BP, Tesla is a definite ‘shopping list’ stock,” Keith told me back then. “We’ve been nibbling at it here, and have played it successfully several times. But it’s not yet at the point where I’m ready to jump all the way in. I think my rationale behind Tesla remains upbeat. I mean, you’ve got a real winning combination here – a disruptive sales model, a CEO who’s the most innovative guy on the planet, all the capital in the world that can be brought to bear. I don’t give a rat’s [tail] that New Jersey won’t let the company sell its cars there. There are much bigger opportunities. Wait ’til you see what the company does with China.”

Sometimes I think Keith has a “crystal ball” in his hip pocket…

  • Featured Story

    Three Orphan Drug Stocks to Buy When the Biotech Market Is Down

    best biotech investments 2014

    There's no sugarcoating it: Biotech stocks have had a rough run in the past month.

    But when other investors are running for the hills, Money Morning experts are finding profit plays. With biotech stocks trading lower, there are excellent buy-in opportunities on valuable biotech companies.

    Orphan drugs offer some of the best profit plays in biotech as the have extremely lucrative markets cornered.

    And these three stocks to buy are the best orphan drug plays now...
  • biotech stocks to buy

  • There Is No Biotech Bubble; Here's the Real Story 20140331_IPO-bubble

    Some analysts feel that the biotech sector's recent tumble is evidence of the biotech bubble bursting.

    But they're wrong; the market is simply in a period of adjustment.

    The premise behind the bubble idea is that biotech companies as a group are overvalued, that their market caps aren't supported by performance. In other words, that their perceived value is all smoke and mirrors.

    The problem with that argument is, these analysts are using a mass of technical indicators to support it. Anyone who's followed start-up biotechs knows that's a fool's errand.
  • Finding the Blockbuster That Will Make You Rich In the pharmaceutical industry, a "blockbuster" is any drug that brings in $1 billion or more in revenue per year. It's the prize that every biotech hopes to win - and every biotech investor hopes to cash in on. So how do you spot one in the making? If the market suspects a drug candidate has blockbuster potential, catalysts (events like positive clinical study results and regulatory milestones) will give its manufacturer's share price a big, big boost. There is no crystal ball that's 100% accurate when experimental drugs are concerned, but here are some telling questions that can narrow your search... Full story...
  • The Secret Behind This Controversial Industry's Leader As a long-time tech-investing analyst, I have one of the best vantage points in the country for tracking profitable marijuana industry trends.
    Here's the thing: I live 10 minutes from the epicenter of the medical marijuana movement in northern California, and the rest of the nation for that matter.
    Downtown Oakland contains a small cannabis-friendly district known as "Oaksterdam." In fact, there's a patient co-op across the street from a store where I buy my fedoras.
    I bring all this up so you know I've followed what's been happening with the marijuana legalization movement for years.
    In these parts, it's difficult to avoid - you see lots of folks walking around wearing their official Oaksterdam t-shirts.
    Since California legalized medical marijuana in 1996, another 19 states have joined the movement.
    The San Francisco-based market research firm ArcView Group estimates the national legal marijuana market at $1.53 billion in 2013. ArcView expects sales to nearly double to $2.57 billion by the end of this year
    Clearly, the industry is growing rapidly, and there's big money to be made... especially if you hear about its best profit play... Full Story
    Read More...
  • Double Your Money with Our "High-Tech GPS"

    Early last year, I saw a research study that said nearly 60% of all U.S. workers have a net worth of less than $25,000.

    And that means they have no retirement.

    From the moment that I saw that research, I knew I had a mission - to help folks reclaim their financial futures by breaking free of Wall Street's self-serving shackles... and creating wealth all on their own.

    And I knew there was one avenue to travel - the high-tech highway.

    So I developed a roadmap - a set of five rules - that would serve as a kind of "tech-investing GPS." My goal was to help investors identify "double-your-money" tech stocks - and navigate their way to massive high-tech wealth.

    Today I'm going to walk you through those rules again, and also give you a bonus - a biotech stock with double-your-money potential.

    So let's get started...
  • Three Bioscience Breakthroughs You Can't Afford to Miss You can make huge gains investing in a breakthrough drug, but you can do even better putting your money into a new, cutting-edge technology platform that can fuel a company's entire pipeline. One biotech I recommended to my BioScience Millionaire subscribers last July, Sangamo Biosciences Inc. (Nasdaq: SGMO), has developed a technology from naturally occurring molecules, called zinc finger proteins (ZFPs), that scientists can engineer to edit specific genes in the human genome. It can cut them out, replace them, or add new ones - in other words, it plays with the basic building blocks of life as if they were Lego pieces! Sangamo is currently using ZFP technology to find cures for some of the most intractable - and often un-druggable - diseases we know of, including HIV, Alzheimer's, Huntington's, and Down's syndrome to name a few. And Sangamo isn't the only company using ZFPs for research. In fact, it licenses out the technology to scientific institutions and companies all over the world - providing it with a great revenue stream. As a result, SGMO shares have gone up more than 150% since last summer. Actually, if you'd had the foresight to buy the stock at the beginning of 2012, you'd now be realizing profits of 577% on your money. The magic word in that sentence is "foresight." The trick is to spot these technologies early in their development, either before they've had IPOs or soon after. With that in mind, here are a few exciting new technologies to keep an eye on... Full Story Read More...
  • Penny Stocks to Watch Top 10 Penny Stocks this year

    The recent spate of uninspiring data, from unemployment to retail sales, has been blamed on the unrelenting cold and snowy winter. But one group that hasn't been affected, and isn't using the convenient "bad weather" excuse, is this list of penny stocks to watch now.

    This week brought huge gains from several low-priced stocks across all sectors:

    Here are four penny stocks to watch now.
  • This Patent Cliff 2014 Chart Shows How Much Revenue Big Pharma Will Lose diver

    More pharmaceutical companies will lose drug patents to the patent cliff in 2014, threatening billions of dollars in revenue for Big Pharma.

    Patent Cliff 2014 chart

    Once a drug is off patent, other pharmaceutical companies are free to replicate the product. That can drastically slash the revenue of pharmaceutical companies that have been making billions of dollars from their patented products.

    Not all patent-cliff companies face immediate competition, but they do face huge threats to their revenue. And that can worry investors.

    Just look at this patent cliff chart illustrating how much the biggest pharmaceutical companies stand to lose:

    Patent Cliff 2014: Who Stands to Lose

    To continue reading, please click here...
  • Penny Stocks: Today's Biggest Movers Today's Penny Stock Earnings

    A number of penny stocks showed investors some love today (Friday) with huge share-price climbs.

    While the Dow Jones Industrial Average rose just under 1% by 2 p.m., these hot penny stocks were up double digits.

    Following are five of Friday's biggest low-priced movers.
  • Investing in Tech: We Sure Hope You Own These Three "Wealth Building Blocks"

    I get a lot of questions from you folks here at the Strategic Tech Investor.

    And the single most frequently asked query is this one:

    "Michael, what's the best way to get started as a tech investor?"

    I'll grant you: As questions go, that's probably the most basic one that you'll find.

    To continue reading, please click here...
  • Bypass These Pitfalls to (Major) Profits in Bioscience Anyone who's very familiar with the bioscience/pharmaceutical sector will tell you investing in experimental drugs can be an object lesson in volatility. As the drugs progress toward FDA approval or denial, the stock prices of the companies backing them can be in for the same volatile ride. A stock's surge or decline is often premised on general assumptions about the likelihood of FDA approval. But within specific bioscience sectors, that likelihood varies... widely. That's why I wanted to navigate through some types of drugs that generate a lot of enthusiasm but often crash before delivery. That way you can avoid some of the downside risk of this often lucrative market...
  • Cadence Pharmaceuticals (Nasdaq: CADX) Stock Climbs 26% in Latest Biotech Deal Pharma

    What a year so far for biotech stock profits...

    Another consolidation in the active biotech sector came Tuesday when Cadence Pharmaceuticals Inc. (Nasdaq: CADX) agreed to be acquired by Mallinckrodt plc (NYSE: MNK) in a $1.3 billion deal. The move sent CADX up 26%.

    Under terms of the deal, Dublin, Ireland-based Mallinckrodt will pay $14 in cash for each share of San Diego, Calif.-headquartered Cadence. That's a 26% premium to Monday's closing price and a 32% premium to the stock's average 30-day trading price.

    To continue reading, please click here...
  • The Best Biotech Takeover Targets for 2014 cliff

    This could be the biggest year ever for investing in biotech takeover targets - all due to the patent cliff.

    The "patent cliff" refers to the sharp revenue drop a pharmaceutical company faces when the patent on one of its drugs expires. At that point, other drug companies can begin replicating name-brand drugs, cutting into the billions of dollars in revenue that large-cap pharmaceutical companies are used to.

    To continue reading, please click here...
  • IPO Calendar 2014 Dominated by Biotech best biotech investments 2014

    IPO Calendar 2014: This year is forecast to be a record year for initial public offerings (IPOs).

    Over the January to March period, some 250 to 300 new issues will launch, according to professional services firm EY - a number not seen since the start of the 2008 financial crisis.

    And biotech companies are the hottest issues to date.

    Since 2000, no two-week period saw more than six new biotech issues - until now.

    See which biotech IPOs could be the best investments now...
  • Furiex Pharmaceuticals (Nasdaq: FURX) Stock Up 130% Today on This "Blockbuster Drug" News

    While gains were modest across the three major benchmarks today (Tuesday), there was nothing modest about these major gains for Furiex Pharmaceuticals (Nasdaq: FURX) stock.

    Shares of Furiex more than doubled in value, surging some 150% intraday. The closed up 129.91% at $105.69. The reason: The company announced that its experimental drug eluxadoline significantly alleviated diarrhea and abdominal pain, which typically accompany irritable bowel syndrome (IBS), in two large late-stage trials.

    To continue reading, please click here...
  • Best Penny Stocks: Why Biotech Keeps Delivering Triple-Digit Gains best biotech investments 2014 Some of the top biotech penny stocks we recommended last year gained as much as 440%, 231%, and 214%. And the biotech sector is going to keep surging - especially the sector's best low-priced buys. We've already identified some of this year's winners - With that in mind, following are three of the best penny stocks in biotech.